Triple-action weekly weight-loss drug reduces sleep apnea in two late-stage trials

AI Summary

A triple-action weekly weight-loss drug reduced sleep apnea in two late-stage clinical trials. The findings suggest the treatment may help address a serious condition linked to repeated breathing interruptions and reduced blood oxygen during sleep.

Sleep apnea often gets passed off as mere snoring, but it's a much bigger deal. Throughout the night, breathing keeps pausing, and each pause chips away at sleep quality. Left untreated, repeated breathing disruptions and drops in blood oxygen during sleep can do far more than leave you groggy in the morning—they can take a serious toll on long-term health.